TXG
10x Genomics, Inc.
Stock
$93.50+4.74 (+5.34%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $127M | $136M | $6.7M | −$15M | −$34M | −$21M | −$218M | $35M | −$76M | −$11M |
| Capital expenditures | $5.6M | $5.9M | $12M | $49M | $132M | $101M | $37M | $43M | $6.3M | $3.8M |
| Free cash flow | $121M | $130M | −$5.7M | −$64M | −$165M | −$123M | −$255M | −$8.1M | −$83M | −$14M |
| Stock-based compensation | $99M | $109M | $141M | $167M | $137M | $96M | $49M | $13M | $2.7M | $1.7M |
| Buybacks | — | — | — | — | — | — | — | — | — | $80K |
| Free cash flow margin | 19.7% | 20.2% | −0.9% | −10.3% | −32.0% | −25.0% | −85.2% | −3.3% | −56.5% | −20.3% |